DAVID MANGELSDORF, PhD
University of Texas
Alfred G. Gilman Distinguished Chair in Pharmacology; Raymond and Ellen Willie
Distinguished Chair in Molecular Neuropharmacology, University of Texas
Southwestern Medical Center
Dr. David J. Mangelsdorf is the Alfred G. Gilman Professor and Chair of the Department of Pharmacology at the University of Texas Southwestern Medical Center in Dallas, an Investigator of the Howard Hughes Medical Institute and a member of the National Academy of Sciences. Dr. Mangelsdorf runs a joint laboratory with Dr. Steven Kliewer, and together their research team is focused on nuclear receptor regulation of metabolism. This work led to the discovery of two new signaling pathways mediated by the endocrine factors FGF19 and FGF21, which govern metabolism in response to nutrient stress. Their research has uncovered several therapeutic targets that are being developed to treat diverse diseases such as obesity, diabetes, fatty liver disease, cholestasis, and even nematode parasitism.